Q-omics provides the consensus-scored TMEM200B profile across patient tissues and cancer cell-line models. TMEM200B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM200B is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, TMEM200B RNA expression shows 18,748 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, HNSC, and THYM as cancer lineages where TMEM200B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM200B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM200B survival associations across molecular data types. TMEM200B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM200B RNA expression–survival associations across cancer types. High TMEM200B expression shows unfavorable associations in ACC, UVM, BLCA, LGG and STAD, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM200B RNA expression.
This table summarizes TMEM200B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM200B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM200B shows lower tumor expression in KICH, THCA, BLCA and COAD and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher TMEM200B RNA expression in tumor versus normal tissue (log2 FC = +1.477, t-test p < 0.001).
This table shows molecular features associated with TMEM200B in patient tissues and cancer cell lines. In patient samples, TMEM200B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM200B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
